Becky Taub and Paul Friedman, are leading the efforts of Madrigal Pharmaceuticals to develop the first treatment for NAFLD/NASH. That drug is called Resmetirom and is currently in phase 3 trials. Many observers think they will be the first to have a successful drug for fatty liver disease.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of fatty liver and cardio-metabolic diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO- NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients.
Madrigal recognizes that compounds with greater selectivity for thyroid hormone receptor (THR)-β and liver uptake has the greatest potential to overcome challenges faced by prior, less selective compounds and deliver the full therapeutic potential of THR-β agonism. The Company believes that resmetirom, its lead product candidate, is the first orally administered, small-molecule, liver-directed, truly β-selective THR agonist.
Resmetirom has demonstrated the potential for a broad array of therapeutically beneficial effects, not only by improving the non-alcoholic steatohepatitis (NASH) phenotype through reducing liver fat and liver inflammation, and by restoring hepatocytes to normal function, but also by decreasing levels of multiple atherogenic lipids. These pleiotropic actions, coupled with an excellent safety profile, suggest that resmetirom could be the preferred option for treating NASH and for addressing the heightened cardiovascular risk in non-alcoholic fatty liver disease (NAFLD)/NASH patients.
Wayne Eskridge published There is a new ELF in town, sorry no magic this time, but important anyway in Voices - our blog 2021-09-06 20:50:05 -0600
ELF, cute little name but what does it mean to liver patients?
ELF was just approved as a blood test for fibrosis by the FDA and this is an important step in the efforts to develop better tools for diagnosing advanced liver disease and getting away from liver biopsy.
Wayne Eskridge published The CDC talked to me like an adult, sadly I woke up, it was just a dream in Voices - our blog 2021-08-16 16:18:05 -0600
I'm sympathetic to the challenge the CDC faces but I hate the way they dumb down their messages about this virus. By talking to us like we are 6th graders they just add to the confusion. There are things you need to understand about this virus so that you can respond appropriately. See the summary notes below.Read more
Wayne Eskridge published Survey says...liver patients need to be identified to be more aware of their risks in Voices - our blog 2021-08-13 11:42:55 -0600
Recently, we sent out a survey to our community to get an idea about COVID-19 vaccines and their impact among immunocompromised people with liver disease. We knew we were posing this survey to our community, which is likely more informed and focused on fatty liver disease, so these results should be considered in that context. Though we did not achieve statistical significance with any of our findings, thanks to you, we got over 100 responses and found some interesting, yet not completely surprising, insights. Click on the image below to see the top line results from the survey.
Wayne Eskridge published Virus mutation factories, how might you become one of them? in Voices - our blog 2021-08-10 08:44:06 -0600
Twenty million people with the liver disease NASH, or non-alcoholic steatohepatitis, are also more likely than the average person to be infected with the COVID Delta variant and suffer from long COVID. Many of these chronically ill will become variant factories increasing the risk of developing new and deadlier strains. We’re working hard to prevent that, aren't we?Read more
Wayne Eskridge published Medical care, I don't know whether I'm mad or sad, It is worse than I feared in Voices - our blog 2021-07-27 13:35:00 -0600
I really want to be mad at someone, but who?
You are here because you have an interest in health. Suppose you had a dangerous condition that takes a decade or two to develop but had no symptoms. Would it matter to you if no one told you?
Buzz off you say??? Life is like that you say, lots of things happen to people. There's nobody to blame. It's in the fine print on the back of the ticket. Life isn't fair and no one gets out alive. Don't waste the energy thinking it can be better?Read more
Wayne Eskridge published COVID mutations, vaccines, chronic disease -- things you need to know in Voices - our blog 2021-05-10 14:19:44 -0600
Infection rates and vaccine failures - some points to ponder
We have been seeing the headlines about the COVID tragedy in India as hospitals turn patients away and the nation runs out of oxygen as people are literally dying in line waiting to refill oxygen tanks. India faces a historic crisis and you probably imagine the densely packed cities and poverty are the cause. But wait, what about the REST OF THE STORY?
If you or someone you care about has a chronic disease, there are things about the story of India that will likely affect you in coming months. I've written about COVID variants before, click here for a review. The UK strain has become the dominant variant in the US and it has done that because it is about 50% more infectious than the Wuhan original. The University of British Columbia recently released an actual image of the UK variant spike protein which helps us understand that. The image is an amazing science story about how they could take this picture but a story for another time.
Contact for help accessing patient support and cost reduction programs.
Scott Ritchey is an account executive who works with Xifaxan and patients suffering from HE. I have discussed the problem that many patients have with insurance coverage and drug costs and he has volunteered to help people connect to the proper resources for free or reduced cost medication. Here is his contact information. If you contact him you can tell him that I referred you to him if you wish.
Scott D. Ritchey
Regional Account Executive – Mid Atlantic
Wayne Eskridge published I can see clearly now, the patient journey through liver land in Voices - our blog 2021-04-21 06:58:55 -0600
In the doctor/patient relationship there is a physician process which is called the "intention to diagnose". That may seem odd, but diagnosis requires a deliberate action by the doctor. You may be more familiar with the idea of the "intention to treat". You may have heard the argument that there is no value in identifying a condition if it can't be fixed and in that case there is no intention to treat so no intention to diagnose.
As a liver disease patient you may have learned about your condition when you were fairly advanced. Why does that happen? Is it a lack of the intention to diagnose, a failure of diagnosis, inadequate tools or training, or is something else happening? We are hosting a webinar on Wednesday the 17th at 12:00 Eastern. We will be discussing non-invasive testing with a couple of experts, Dr Mona Munteanu and Dr Stephen Harrison, and we will talk about the diagnosis problem and the several tools available for detection and monitoringRead more
Wayne Eskridge published Ambassador Donation Portal in Wellness Ambassadors 2021-03-09 15:44:03 -0700
Wayne Eskridge published Non-invasive screening and genomics in NAFLD in Voices - our blog 2021-02-28 15:49:30 -0700
We have had a series of webinars about the disease and cutting edge research. Now we would like to focus on the future for the patient. Covid wrecked our plans for SUNN-2, the next step in our plan to eventually screen 1,000,000 patients a year for liver disease, but with vaccines we can begin to think about that future.
I'd like to invite you to a webinar where we will look to the future and some of the tools that are going to help us in our battle with the noncommunicable diseases that have become the scourge of our time. Let me challenge you to step back from COVID for a couple of minutes and think about health more broadly. One small step is to attend this webinar.Read more
Wayne Eskridge published Damned Liver, How do I monitor thee? in Voices - our blog 2021-02-23 16:24:40 -0700
I finally got a chance to get the COVID vaccine. As a guy with chronological superiority (fancy talk for I'm older than most) and a high risk category with NASH/cirrhosis this is a big deal.
I keep seeing comments from NASH patients who say they are not going to get the vaccine. That is a risky strategy. I understand the concern but even beyond the risk of dying from COVID, I personally am concerned about the long Covid symptoms that are being reported. Think about that. You are dealing with issues now. As a compromised patient, even if you survive infection, might the odds of lingering problems on top of what you already have be greater. That possibility concerns me and is part of why I want the vaccine.Read more
The first project of the Wellness League is called the SUNN Screen project. We want to gather blood tests of people with liver disease using the LIVERFASt (click here for more information) test as part of our project to encourage doctors to screen for asymptomatic liver disease. Even though we know that about 100 million Americans have fatty liver disease the medical profession does not support screening for advancing disease absent symptoms. We believe that people should learn about their risks before they become ill. Our SUNN project is our effort to gather data needed to change that guidance.
The first step is to consider becoming part of the Wellness League. This consent form will allow our staff to contact you and provide you with all of the information you need. This is not a public group. It is intended to serve real people dealing with health and is not a place for lurkers or trolls. The Foundation website is open to all. The Wellness League is patient only.
Wayne Eskridge published DUMMY, you never say what you think on the internet in Voices - our blog 2021-01-31 09:31:27 -0700
The times we live in can make discussion difficult. So much of what we see in the news every day is inflammatory and negative emotion stalks the land. I recently wrote about the importance of getting the COVID vaccine and I was not kind in my view of people who advise others not to be vaccinated. I got a bit of criticism for expressing my opinion. Knowledge can sometimes get past emotional responses so fair warning. I'm going to teach a small class here in how this virus and the vaccine really work. Stay with me, it is a really interesting story and matters to your health.
We have all seen these picture of the coronavirus with all the spikes sticking out of the surface. Interesting as an art project but that image only hints at what is going on. In this explanation we are going to dive into what really happens. Don't worry, life is infinitely complex but you can understand this.
Lets look first at those spike proteins. Calling them spikes makes a headline that editors like but they are really more like ugly little mushrooms.Read more
Wayne Eskridge published Afraid of the COVID Vaccine? No No, You need this information in Voices - our blog 2021-01-30 09:04:43 -0700
I keep hearing from people who have decided not to get vaccinated or who are fearful of the vaccine and don't know what to do.
I don't know if I can express how sad that makes me for those people and their families or how profoundly angry I am at people who promote fear about the vaccine without evidence.Read more
Wayne Eskridge published Non-invasive blood tests for liver disease - an update in Voices - our blog 2021-01-16 16:54:59 -0700
What is the situation with blood tests for fatty liver disease today?
The table above was produced by Fibronostics. We have followed the development of their program for a couple of years and they are supporters of the foundation. The thing that caught my attention back in 2018 was that their test, like the earlier Fibrosure was the result of artificial intelligence studies. A lot of AI is being done today but those two were early developers and I felt that this would be the future for us as patients. The downside, of course, is that tests like these are proprietary so the costs are higher so the question of who should use them is more complicated. For me, as a patient, I wish such tools had been available to me early on in my disease so that I might not have ended up as a cirrhotic.Read more
Wayne Eskridge published Thoughts at a hinge point in liver disease management in Voices - our blog 2020-12-24 13:13:43 -0700
Everyone writes uplifting letters this time of year. Personally Rosemary and I are doing well and our best hopes are for all of you as we speed toward the next chapter of our lives. The GRAND CONJUNCTION of Jupiter and Saturn reminded me of my youth and the AGE OF AQUARIUS. Something for those with a few minutes for a bit of nostalgia.
There are a lot of mixed currents in this section of the river of time that we find ourselves.
Fatty Liver Foundation organizer
As a liver disease patient my goal is to help others understand, manage, or prevent the disease